Advertisement


Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Advertisement